Moderna’s oncology pipeline also includes a Merck-partnered personalized cancer vaccine called intismeran autogene or ...

While most of what the FDA laid out in a recent draft guidance on the assessment of overall survival in oncology clinical ...

With $70 million and a phase 2 ready asset in hand, British biotech Elevara Medicines has emerged to try to revolutionize the ...

A retinal implant developed by Science Corp. has for the first time restored some functional vision to patients with a severe ...

It is financial reporting season, and a few major medtech companies posted third-quarter sales growth. | It is financial ...

The program in question is Neuphoria’s BNC210, also known as soclenicant, an α7 nicotinic receptor negative alteration ...

In 2015, Bluestone led a small clinical trial to isolate and grow Tregs from diabetes patients and then reinfuse the cells ...

Unless a white knight emerges to rescue the business, Galapagos will start a wind-down process that will affect around 365 ...

Walmart will become the first U.S. retailer to sell Abbott’s continuous glucose monitoring device as the medtech giant looks to broaden its sales potential for its growing business unit. | Walmart ...

Meanwhile, AstraZeneca’s Enhertu partner Daiichi arrived at ESMO armed with its own ADC data for the cadherin-6-targeting ...

Under the terms of a deal that rescued the once-rejected tebipenem HBr, GSK will file for approval of the oral antibiotic. Back in 2022, after the FDA requested another phase 3 trial and denied ...

After rejecting Replimune’s melanoma drug RP1 this summer, the FDA has accepted the biotech’s resubmission of an approval ...